Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) and BioAtla (NASDAQ:BCAB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Insider & Institutional Ownership
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Bicycle Therapeutics and BioAtla”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bicycle Therapeutics | $61.20 million | 4.01 | -$218.96 million | ($2.73) | -1.29 |
| BioAtla | $8.50 million | 0.25 | -$59.61 million | ($25.45) | -0.05 |
BioAtla has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Bicycle Therapeutics and BioAtla’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bicycle Therapeutics | -311.11% | -33.22% | -27.79% |
| BioAtla | N/A | N/A | -289.67% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Bicycle Therapeutics and BioAtla, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bicycle Therapeutics | 1 | 3 | 5 | 0 | 2.44 |
| BioAtla | 1 | 0 | 1 | 0 | 2.00 |
Bicycle Therapeutics currently has a consensus price target of $13.86, indicating a potential upside of 294.79%. BioAtla has a consensus price target of $200.00, indicating a potential upside of 15,284.62%. Given BioAtla’s higher probable upside, analysts clearly believe BioAtla is more favorable than Bicycle Therapeutics.
Risk and Volatility
Bicycle Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Summary
Bicycle Therapeutics beats BioAtla on 9 of the 14 factors compared between the two stocks.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
About BioAtla
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
